Diabetic foot disease in a patient with multiple myeloma receiving thalidomide.
Pitini
V
V
Oncologia Medica e Trapianto di Midollo Osseo, Pad. H 5  piano; Policlinico Universitario, Via Consolare Valeria, 98125   Messina (Italy). pitini@ciaoweb.it
Arrigo
C
C
Aloi
G
G
Azzarello
D
D
La Gattuta
G
G
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D003097:Collateral Circulation / Q000187:drug effects; D003131:Combined Modality Therapy; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D017719:Diabetic Foot / Q000139:chemically induced / Q000209:etiology*; D003929:Diabetic Neuropathies / Q000503:physiopathology; D016228:Endothelial Growth Factors / Q000502:physiology; D005260:Female; D005528:Foot / Q000098:blood supply; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007511:Ischemia / Q000139:chemically induced; D008222:Lymphokines / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D012008:Recurrence; D016879:Salvage Therapy; D013792:Thalidomide / Q000009:adverse effects* / Q000627:therapeutic use; D019851:Thrombophilia / Q000139:chemically induced; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D013792:Thalidomide